Robert C. Green, MD, MPH is Professor of Medicine at Harvard Medical School, and directs the Genomes2People Research Program and the Precision Population Health Initiative at Mass General Brigham, the Broad Institute, and Ariadne Labs. Originally trained as a neurologist and epidemiologist, he contributed for over a decade to the clinical characterization, treatment trial methodology, and risk refinement for Alzheimer’s disease. Since he re-trained as a medical geneticist, he conducts empirical research on the medical, behavioral, and economic outcomes around the implementation of genomic medicine. Dr. Green led the first NIH-funded trials disclosing common complex disease risk (REVEAL Study) and the first prospective study of direct-to-consumer genetic testing (PGen Study). He currently leads and co-leads the first randomized trials to explore the implementation of medical sequencing in adults (MedSeq Project) and newborns (BabySeq Project). Dr. Green currently mentors junior faculty members and postdoctoral researchers, all currently or previously funded through NIH training grants and/or early career awards, and serves as Associate Director of the T32 Training Grant in Genetics at Brigham and Women’s Hospital, as well as a mentor for several other T32 grants.